Janiczek Wealth Management’s Globus Medical GMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$19.8K Hold
289
﹤0.01% 560
2024
Q1
$15.5K Sell
289
-38
-12% -$2.04K ﹤0.01% 610
2023
Q4
$17.4K Buy
327
+231
+241% +$11.3K ﹤0.01% 569
2023
Q3
$4.77K Sell
96
-127
-57% -$7.1K ﹤0.01% 732
2023
Q2
$13.3K Sell
223
-515
-70% -$29.4K ﹤0.01% 523
2023
Q1
$42.5K Sell
738
-646
-47% -$41.4K 0.01% 333
2022
Q4
$102K Buy
1,384
+7
+0.5% +$477 0.03% 221
2022
Q3
$80K Buy
1,377
+752
+120% +$45.3K 0.03% 232
2022
Q2
$37K Sell
625
-203
-25% -$13.3K 0.01% 351
2022
Q1
$61K Buy
828
+436
+111% +$30.3K 0.02% 277
2021
Q4
$28K Buy
392
+93
+31% +$6.75K 0.01% 427
2021
Q3
$23K Buy
299
+88
+42% +$7.07K 0.01% 430
2021
Q2
$16K Buy
211
+55
+35% +$3.91K 0.01% 472
2021
Q1
$10K Sell
156
-14
-8% -$887 ﹤0.01% 528
2020
Q4
$11K Buy
170
+110
+183% +$6.32K 0.01% 456
2020
Q3
$3K Buy
+60
New +$3.1K ﹤0.01% 438

Other funds holding GMED

Janiczek Wealth Management's GMED Position: Q2 2024 in Review

Janiczek Wealth Management held its Globus Medical (GMED) position steady in Q2 2024 at 289 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Janiczek Wealth Management first reported a position in GMED in Q3 2020 and has held it in 16 quarters since. The position peaked at $102K in Q4 2022. 450 funds tracked by Wall St. Rank hold GMED as of Q2 2024.

  • Janiczek Wealth Management held 289 shares of Globus Medical worth $19.8K as of Q2 2024.
  • Janiczek Wealth Management left its Globus Medical share count unchanged in Q2 2024.
  • Globus Medical made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #560 holding.
  • Janiczek Wealth Management first reported a position in Globus Medical in Q3 2020 and has held it in 16 quarters since.
  • Janiczek Wealth Management's Globus Medical position peaked at $102K in Q4 2022.
  • 450 funds tracked by Wall St. Rank held Globus Medical as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.